Overview
Description
Hansoh Pharmaceutical Group Co., Ltd. is a holding company, which engages in the research and development, production, and sale of a series of pharmaceutical products. Its products include oncology, anti-infective, CNS diseases; metabolic and other diseases. The company was founded by Hui Juan Zhong on December 2, 2015 and is headquartered in Shanghai, China.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals China
Financials
Key metrics
| Market capitalisation, EUR | 25,649 m |
| EPS, EUR | - |
| P/B ratio | 6.7 |
| P/E ratio | 44.4 |
| Dividend yield | 0.95% |
Income statement (2024)
| Revenue, EUR | 1,575 m |
| Net income, EUR | 562 m |
| Profit margin | 35.66% |
What ETF is Hansoh Pharmaceutical Grp in?
There are 27 ETFs which contain Hansoh Pharmaceutical Grp. All of these ETFs are listed in the table below. The ETF with the largest weighting of Hansoh Pharmaceutical Grp is the JPMorgan Global Emerging Markets Research Enhanced Index Equity SRI Paris Aligned Active UCITS ETF USD (dist).
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
